Closely-held Cannabotech of Israel reports that its cell model study results have shown that its integrative colon products killed more than 90% of colon cancer cells in a cell model experiment.
The integrative colon products are based on a combination of several cannabinoids from the cannabis plant and various fungal extracts.
The study examined the effect of Cannabotech’s integrative colon products on various colon cancer subtypes, representing different molecular changes common in these colon cancer subtypes.
The fungal extracts contain, among other things, an enriched and high concentration of an active substance called PSK, extracted from the Trametes fungus, known for its anti-cancer properties and which has been approved as an oncology treatment in Japan, Taiwan and South Korea.
The formula’s effectiveness will be examined in combination with standard chemotherapies during the next stages. Moreover, the cannabinoid formula will be combined with the fungus, Cyathus Striatus, as part of the botanical drug development project led by the University of Haifa.
In a statement, Cannabotech CEO, Elhanan Shaked, said the integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment to reduce side effects.
“Cannabotech’s solutions will be launched in Israel and the U.S. towards the second half of 2022, while the company’s goal is to define a new standard for the medical cannabis industry,” he added.
Senior oncologist, Prof. Tami Peretz, said Cannabotech’s Integrative products are unique in that they are designed to standards similar to those of the pharmaceutical industry and incorporate many active ingredients.
“The company’s products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory. Based on these experiments, there is room to perform animal studies and, in the future, to examine the possibility of incorporating these products in colorectal cancer patients.”
Isaac Angel, Cannabotech’s pharmacological consultant, said the significant synergistic effect demonstrated by the combination of active ingredients was achieved without the presence of THC, which is the cannabinoid substance producing the “high” effect. Each of the other cannabinoids tested individually demonstrated different effects on the various cell types.
